Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded May 20, 2025 · Filed May 20, 2025
The CFO of Relmada Therapeutics paid $31K out of pocket for Relmada Therapeutics shares. 3 other people at Relmada Therapeutics bought some too, in the same month. Shares held went up 26% with this purchase.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$31,422
Shares × reported transaction price
$25K–$100K
+26.3%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
First purchase in 0 months
Confirmed open-market purchases by the same insider in the available history
No
Compared with 2 earlier confirmed purchases
4 distinct insiders in 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
This purchase equals about 3.2% of the average reported total pay of the company's named executive officers other than the CEO, fiscal 2024 ($988K)
An average across the officers named in the pay versus performance table of the company's proxy statement (DEF 14A), filed 2026-04-17. This person may not be one of them, so it is not their own pay. A size comparison, not a judgement
54 days after results of Mar 27, 2025, 79 days before results of Aug 7, 2025
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
None found in footnotes
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +39.6% | +0.8% | +38.8% |
| 30 days | +30.7% | +2.0% | +28.7% |
| 90 days | +19.6% | +9.8% | +9.8% |
| 180 days | +664.5% | +14.2% | +650.3% |
| 365 days | +1288.4% | +27.4% | +1261.0% |
Past results only. Not a forecast.
Insider buying
Traded May 16, 2025 · filed 4 days later
The CEO of Relmada Therapeutics paid $77K out of pocket for Relmada Therapeutics shares. 3 other people at Relmada Therapeutics bought some too, in the same month. Shares held went up 45% with this purchase.
Insider buying
Traded May 19, 2025 · filed 1 day later
The CEO of Relmada Therapeutics paid $15K out of pocket for Relmada Therapeutics shares. 3 other people at Relmada Therapeutics bought some too, in the same month. Shares held went up 5% with this purchase.
Insider buying
Traded May 20, 2025 · filed the same day
The CEO of Relmada Therapeutics paid $82K out of pocket for Relmada Therapeutics shares. 3 other people at Relmada Therapeutics bought some too, in the same month. Shares held went up 25% with this purchase.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
